title: Prevalence and correlates of postdiagnosis initiation of complementary and alternative medicine among patients at a comprehensive cancer center.
abstract: OBJECTIVE
  Patients with cancer increasingly use complementary and alternative medicine (CAM) in conjunction with conventional oncology treatments. Previous studies have not investigated postdiagnosis initiation of CAM therapies or independent correlates of use of individual CAM modalities. The purpose of this study was to determine the prevalence and correlates of individual CAM modalities initiated after cancer diagnosis.
  
  
  METHODS
  A cross-sectional survey was conducted of a random sample of adults with a cancer diagnosis (N = 1,228) seeking care at a National Cancer Institute-designated comprehensive cancer center within a 12-month period.
  
  
  RESULTS
  The majority of patients were female (64.7%), white (86.9%), and married (72.8%).Three-quarters (75.2%) used at least one CAM modality, and 57.6% of those using CAM initiated use after cancer diagnosis. For all CAM therapies combined, women were 1.7 times more likely than men to initiate any CAM therapy after cancer diagnosis. However, when CAM modalities were differentiated by type, men and women were equally likely to initiate all therapies except for psychotherapy and mind-body approaches. Postdiagnosis initiation of every CAM modality, except mind-body therapies, differed by cancer type.
  
  
  CONCLUSIONS
  A significant proportion of patients initiated CAM use after diagnosis. However, specific type of CAM initiated varied by demographics and cancer type, suggesting there is not a "typology" of CAM user. Optimal comprehensive cancer treatment, palliation, and survivorship care will require patient and provider education regarding CAM use by modality type; improved provider-patient communication regarding potential benefits, limitations, and risks; and institutional policies to support integrated conventional and CAM treatment.
authors: Duke University Medical Center, Durham, NC 27705, USA. Adam.perlman@duke.edu
authors: Adam
authors: A
authors: Perlman
authors: Oliver
authors: O
authors: Lontok
authors: Maureen
authors: M
authors: Huhmann
authors: J Scott
authors: JS
authors: Parrott
authors: Leigh Ann
authors: LA
authors: Simmons
authors: Linda
authors: L
authors: Patrick-Miller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002173:Cancer Care Facilities / Q000706:statistics & numerical data; D000529:Complementary Therapies / Q000379:methods / Q000706:statistics & numerical data*; D003625:Data Collection; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000175:diagnosis / Q000628:therapy*; D015995:Prevalence; D055815:Young Adult
references: Integr Cancer Ther. 2006 Sep;5(3):224-31
references: 16880427
references: Complement Ther Med. 2007 Mar;15(1):21-9
references: 17352968
references: Ann Intern Med. 2008 Sep 16;149(6):369-79
references: 18794556
references: BMJ. 2001 Jan 20;322(7279):161-4
references: 11159578
references: JAMA. 1998 Nov 11;280(18):1569-75
references: 9820257
references: BMC Complement Altern Med. 2011 Nov 08;11:109
references: 22067368
references: Natl Health Stat Report. 2008 Dec 10;(12):1-23
references: 19361005
references: Clin Pharmacol Ther. 2004 Oct;76(4):323-9
references: 15470331
references: Pharmacotherapy. 2004 Nov;24(11):1508-14
references: 15537555
references: J Clin Oncol. 2000 Jul;18(13):2505-14
references: 10893280
references: Cancer Control. 2005 Jul;12(3):158-64
references: 16062163
references: Urology. 2010 Nov;76(5):1182-8
references: 20494414
references: J Altern Complement Med. 2011 Sep;17(9):867-9
references: 21875352
references: Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):80-90
references: 18212810
references: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references: 21685461
references: N Engl J Med. 2000 Jun 8;342(23):1742-3
references: 10841878
references: Adv Data. 2004 May 27;(343):1-19
references: 15188733
references: J Soc Integr Oncol. 2010 Spring;8(2):56-64
references: 20388446
references: Soc Sci Med. 2008 Jan;66(2):439-53
references: 17923180
references: Ann Intern Med. 2001 Sep 4;135(5):344-51
references: 11529698
references: Psychooncology. 2002 May-Jun;11(3):212-20
references: 12112481
references: Cancer J. 2006 Sep-Oct;12(5):425-31
references: 17034678
references: Urology. 2003 Nov;62(5):849-53
references: 14624907
references: Complement Ther Med. 2009 Apr;17(2):92-120
references: 19185267
references: BMC Cancer. 2011 May 24;11:196
references: 21609461
references: Oncol Nurs Forum. 2005 Nov 03;32(6):1115-22
references: 16270107
references: Integr Cancer Ther. 2005 Mar;4(1):14-20
references: 15695473
references: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6972-9
references: 16203790
references: J Clin Oncol. 1998 Jan;16(1):1-2
references: 9440714
references: Int Semin Surg Oncol. 2007 Apr 30;4:10
references: 17470282
references: Integr Cancer Ther. 2005 Dec;4(4):274-86
references: 16282504
references: Breast Cancer Res Treat. 2009 Jul;116(2):311-6
references: 18839306
references: N Engl J Med. 1993 Jan 28;328(4):246-52
references: 8418405
references: JAMA. 1998 May 20;279(19):1548-53
references: 9605899
references: Eur J Pharm Sci. 2009 Mar 2;36(4-5):433-43
references: 19073252
references: J Natl Cancer Inst. 2006 Jul 19;98(14):961-73
references: 16849679
references: Support Care Cancer. 2005 Oct;13(10):806-11
references: 15711946
references: Altern Ther Health Med. 2002 Jan-Feb;8(1):38-9, 42, 44 passim
references: 11795621
references: J Clin Oncol. 2001 Apr 15;19(8):2365-6
references: 11304791
references: Eur Urol. 2009 Jan;55(1):156-63
references: 18294761
references: J Clin Oncol. 2006 Dec 1;24(34):5457-64
references: 17135649